Prolonged Suppression of Plasma LH Levels in Male Rats after a Single Injection of an LH-RH Agonist in Poly(DL-Lactide-Co-Glycolide) Microcapsules
Open Access
- 4 March 1985
- journal article
- research article
- Published by Wiley in Journal of Andrology
- Vol. 6 (2) , 83-88
- https://doi.org/10.1002/j.1939-4640.1985.tb00821.x
Abstract
The authors have examined the effects of a subcutaneous injection of the LH-RH agonist D-Trp6-LH-RH formulated in biodegradable poly(DL-lactide-co-glycolide) microcapsules on plasma levels of D-Trp6LH-RH, LH, and PRL in adult, gonadectomized male rats. Immunoreactive D-Trp6-LH-RH was detectable in the plasma of these animals at 1, 2, 3, and 4 weeks after injection. LH concentrations were greatly reduced 1 week after administering the D-Trp6-LH-RH microcapsule, continued to decrease during the following week, and remained suppressed until the end of the study, 6 weeks after the injection. Plasma PRL levels appeared elevated 1 to 2 weeks after the injection and suppressed thereafter, but these effects were significant only in animals rendered hyperprolactinemic by transplantation of an isologous pituitary under the renal capsule. These results demonstrate that an LH-RH agonist formulated in biodegradable microcapsules and administered as a subcutaneous injection can exert marked biologic effects in rats for at least 6 weeks. These findings also suggest that prolonged exposure to an LH-RH agonist may first produce stimulation, followed by an inhibition of PRL release from both in situ and ectopic pituitaries.Keywords
This publication has 20 references indexed in Scilit:
- Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules.Proceedings of the National Academy of Sciences, 1984
- “MEDICAL OOPHORECTOMY” USING A LONG-ACTING GNRH AGONIST-A POSSIBLE NEW APPROACH TO THE TREATMENT OF ENDOMETRIOSIS.Journal of Clinical Endocrinology & Metabolism, 1982
- SUSTAINED SUPPRESSION OF TESTOSTERONE PRODUCTION BY THE LUTEINISING-HORMONE RELEASING-HORMONE AGONIST BUSERELIN IN PATIENTS WITH ADVANCED PROSTATE CARCINOMAThe Lancet, 1982
- Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.Proceedings of the National Academy of Sciences, 1982
- D-TRP6-ANALOGUE OF LUTEINISING HORMONE RELEASING HORMONE IN COMBINATION WITH CYPROTERONE ACETATE TO TREAT PRECOCIOUS PUBERTYThe Lancet, 1981
- Reversible Inhibition of Testicular Steroidogenesis and Spermatogenesis by a Potent Gonadotropin-Releasing Hormone Agonist in Normal MenNew England Journal of Medicine, 1981
- Induction of prolactin release by LRF and LRF-agonistLife Sciences, 1980
- Pairwise Multiple Comparisons in Repeated Measures DesignsJournal of Educational Statistics, 1980
- Induction of Luteolysis in the Human with a Long-Acting Analog of Luteinizing Hormone-Releasing FactorScience, 1979
- Inhibitory Effects of Long Term Treatment with a Luteinizing Hormone-Releasing Hormone Agonist on the Pituitary-Gonadal Axis in Male and Female RatsEndocrinology, 1979